Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
The present invention provides synthetic immunochemical haptens for the generation of antibodies that are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants with insignificant cross-reactivity to endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.
Owens, SM., Carroll, F., & Abraham, P. (2007). IPC No. U.S. Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs. (Patent No. 7202348).